Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
These are the 10 most shorted ASX shares
Share Fallers
These were the worst performers on the ASX 200 last week
Healthcare Shares
Mesoblast (ASX:MSB) share price jumps 12% on FDA update
Share Market News
ASX 200 (ASX:XJO) midday update: CSL sinks, Qantas' $1.1bn+ first half loss
Share Fallers
Why Blackmores, Mesoblast, Vulcan, and Zip shares are sinking
Share Fallers
Why Afterpay, Cardno, Mesoblast, and Woolworths shares are falling
Share Market News
ASX 200 (ASX:XJO) midday update: Afterpay takeover vote, Woolworths crashes
Healthcare Shares
Mesoblast (ASX:MSB) share price crashes 21% after Novartis terminates agreement
Healthcare Shares
What's the outlook for ASX biotech shares in 2022?
Share Market News
These are the 10 most shorted ASX shares
Share Gainers
These were the best performing ASX 200 shares last week
Share Gainers
Standouts: 3 ASX biotech shares that outperformed in November
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
